HIV protease inhibitor combinations

Abstract

Combinations of certain HIV-1 protease inhibitors are provided which effectively inhibit the HIV-1 protease enzyme while eliminating or substantially reducing the viral cross-resistance seen with use of individual HIV-1 protease inhibitors. Such combinations are useful in the treatment of diseases associated with the AIDS virus.

What is claimed is: 
     
       1. A method for the prophylaxis or treatment of a disease caused by the HIV virus in a human patient, which comprises administering to said patient, either sequentially or concurrently, an effective HIV-inhibiting amount of an HIV-1 protease inhibitor compound of the formula ##STR44## or a pharmaceutically acceptable derivative thereof, and an effective HIV-inhibiting amount of one or more protease inhibitor compounds selected from the group consisting of (a) the compound of the formula ##STR45## or a pharmaceutically acceptable derivative thereof, (b) the compound of the formula ##STR46## or a pharmaceutically acceptable derivative thereof, (c) the compound of the formula ##STR47## or a pharmaceutically acceptable derivative thereof, (d) the compound of the formula ##STR48## or a pharmaceutically acceptable derivative thereof, (e) the compound of the formula ##STR49## or a pharmaceutically acceptable derivative thereof, and (f) the compound of the formula ##STR50## or a pharmaceutically acceptable derivative thereof, and (g) the compound of the formula ##STR51## or a pharmaceutically acceptable derivative thereof. 
     
     
       2. The method according to claim 1 wherein there is employed the protease inhibitor of the formula ##STR52## or a pharmaceutically acceptable derivative thereof. 
     
     
       3. A method of reducing or eliminating antiviral resistance resulting from administration to a human patient of a protease inhibitor selected from the group consisting of (a) the compound of the formula ##STR53## or a pharmaceutically acceptable derivative thereof, (b) the compound of the formula ##STR54## or a pharmaceutically acceptable derivative thereof, (c) the compound of the formula ##STR55## or a pharmaceutically acceptable derivative thereof, (d) the compound of the formula ##STR56## or a pharmaceutically acceptable derivative thereof, (e) the compound of the formula ##STR57## or a pharmaceutically acceptable derivative thereof, (f) the compound of the formula ##STR58## or a pharmaceutically acceptable derivative thereof and (g) the compound of formula ##STR59## or a pharmaceutically acceptable derivative thereof, or a combination of two or more of said inhibitors, which comprises administering, either concurrently or sequentially, an effective HIV-inhibiting amount of a protease inhibitor having the formula ##STR60## or a pharmaceutically acceptable derivative thereof. 
     
     
       4. The method according to claim 3 wherein the protease inhibitor of formula II, or a pharmaceutically acceptable derivative thereof, is administered in combination with a protease inhibitor of the formula ##STR61## or a pharmaceutically acceptable derivative thereof. 
     
     
       5. A pharmaceutical composition for prophylaxis or treatment of a disease caused by the HIV virus comprising an effective HIV-inhibiting amount of a protease inhibitor compound of the formula ##STR62## or a pharmaceutically acceptable derivative thereof and an effective HIV-inhibiting amount of one or more protease inhibitor compounds selected from the group consisting of (a) the compound of the formula ##STR63## or a pharmaceutically acceptable derivative thereof, (b) the compound of the formula ##STR64## or a pharmaceutically acceptable derivative thereof, (c) the compound of the formula ##STR65## or a pharmaceutically acceptable derivative thereof, (d) the compound of the formula ##STR66## or a pharmaceutically acceptable derivative thereof, (e) the compound of the formula ##STR67## or a pharmaceutically acceptable derivative thereof, (f) the compound of the formula ##STR68## or a pharmaceutically acceptable derivative thereof, and (g) the compound of the formula ##STR69## or a pharmaceutically acceptable derivative thereof in combination with a pharmaceutically acceptable carrier or diluent. 
     
     
       6. A composition according to claim 5 wherein the second protease is the compound of formula ##STR70## or a pharmaceutically acceptable derivative thereof.